Pfizer's attempts to prove Lyrica effective as an epilepsy treatment have delivered mixed results. Just three months ago, the controlled-release formula failed a Phase III trial in adults with epilepsy. But now, the company has unveiled new data showing that Lyrica capsules matched the UCB seizure drug Keppra at reducing a common type of seizures in epilepsy patients.
The study, which tested the formulation as a once-a-day therapy, missed its main goal of changing seizure frequency compared with placebo.
Pfizer's mission to expand Lyrica use just hit a couple of roadblocks.
What does Big Pharma like better than a blockbuster? A bigger blockbuster. And that's just what Pfizer ($PFE) might find in its pain and seizure drug Lyrica. Based on early efficacy data, the company
Pfizer has racked up some positive data for Lyrica in Japan. A new study found that fibromyalgia patients saw a statistically significant reduction in their mean pain score after treatment with
Might Lyrica get yet another indication? As Motley Fool notes, the Pfizer drug just passed a trial for neuropathic pain after spinal cord injury. No detailed data was released, but beating out
Call it a win-win deal. Pfizer and Eisai have restructured their Aricept partnership and entered a new co-promotion deal on Lyrica. The deals ward off a court battle over the Alzheimer's treatment
Is fibromyalgia for real? The question keeps popping up, despite the protests of patient advocates and drugmakers alike. Their contention: That they are educating the public in general and medicine
Taking an antidepressant might help assuage the symptoms of fibromyalgia, a new study finds, but experts caution that does not mean that depression is the cause of the condition. Fibromyalgia
Stringent epilepsy drug black-box labeling is likely to worry consumers and drug manufacturers alike, and will bring the total of drugs with a suicide risk warning up to about 35. The new warnings